Samenvatting
Samenvatting Lecture 6 - Clinical Trials and Clinical Development AM_1180 (AM_1180)
- Instelling
- Vrije Universiteit Amsterdam (VU)
De volledige hoorcollege is samengevat
[Meer zien]Voorbeeld 2 van de 6 pagina's
Voorbeeld 2 van de 6 pagina's
In winkelwagengesponsord bericht van onze partner
Verkoper
Volgen
Voorbeeld van de inhoud
Lecture 6Introduction
● Biggest fear of drug developers: rejection of their outcome/investigations.
● To reduce the chance of rejection: termination of development → because
it's not ethical to redo a finished trial.
● What we want to do: keep close contact with regulators to know their expectations,
whether their CDP (clinical development plan) is good.
● Cover-your-ass management (CYA): as an investigator, eliminating all chances of
being responsible for no valuable data.
● R2 Addendum is new and adds quality management rules in IGH-GCP, it
incorporates RBCM (Risk Based Compliance monitoring). Is defined in chapter
5.0 (sponsor responsibility), but it is so important that it is put at the beginning of the
ICH-GCP.
● What is the impact of Risk Based Approach? Ensuring awareness of all the risks
related to trials and not minimizing but assessing all risks
● What is the probability of them occurring? On these basis you decide which risks are
allowed and which are prevented.
● Source data verification (SDV): process of verifying data that the data indeed came
from participants.
○ Thus sponsors monitor the quality of the data and do 100% SDV.
○ Investigators and trial site verify the database.
● The focus on quality control is not the same: low-experienced trial sites are higher
risk than high-experienced trial sites.
Why the R2 Addendum→ can't do analysis with data until database-lock (DBL)
because of bias.
● New opportunities to increase efficiency and focus on relevant activities
○ Evolutions in technology → electronic data capture (EDC):
computerized system to collect clinical trial data.
○ Risk management processes
● Centralized monitoring offers greater advantage
○ Early access to trial data
○ Running risk analysis
Side-note: The protocol beforehand needs to include the analysis that you will do.
What we can do: look at the general data and compare them with other data.
Like risk analysis with centralized monitoring→ take all the data and analyze it
for sites that have outliers. Potentially find errors and solve them in those sites.
R2 required quality management process steps→ 7 steps of Process Quality
Management:
● Critical process and data identification→ look at trial data and identify
critical data points (risks):
○ Identified during development of protocol
○ Critical Ensure human subject protection • Reliability of trial results
○ Reliability of trial results→ data points (e.g size of tumor,
concentration) that are rare. Critical data is for example the data
that is used to analyze primary end points.
1
, ● Risk identification→ e.g with tumor measurement: not standardized units.
○ Risks to critical trial processes
○ Risks to the critical data points: skewed or not generated properly
○ System level: risks are (consent, safety reporting).
○ Trial level: risks are specific trial and protocol.
● Risk evaluation→ evaluate risks against controls.
○ Change occurrence of the risks vs the detectability
○ The impact on subject protection and reliability of trial
results
○ Remedial actions: what can we do to reduce it. (ICH-
GCP does not mention this, but we take it into
account)
○ The surface area indicates the overall risk. The
smaller the risk evaluation (surface area), the better.
● Risk control→ reduce or accept risks. The approach is proportional to
significance.
○ At all levels (trial & system level)
○ Predefined quality tolerance limits: to what extent we accept risks. It tells
when we need to take action (after x amount of time) and what controls to
take.
● Risk communication
○ Quality management plan including risk management plan
○ Facilitate review
○ This is a continuous process
● Risk review→ risks we can and cannot afford (see ICH-GCP centralized
monitoring)
○ Continuous review of risks
○ Quality tolerance limits
○ Emerging knowledge
● Risk reporting→ predefine the risk as much as you can, but keep the list
updated during the trial (because risks can change during trial). The CSR
should include:
○ Quality management approach
○ Important deviations form tolerance
○ Remedial actions
ICH-GCP E6 (R2) describes centralized monitoring as: Review, that may include
Statistical analyses, of accumulating data from centralized monitoring can be used to:
● Identify missing data, inconsistent data, data outliers, unexpected lack of variability
and protocol deviations.
● Examine data trends such as the range, consistency, and variability of data within
and across sites.
● Evaluate for systematic or significant errors in data collection and reporting at a site
or across sites; or potential data manipulation or data integrity problems.
● Analyze site characteristics and performance metrics.
● Select sites and/or processes for targeted on-site monitoring.
2
Voordelen van het kopen van samenvattingen bij Stuvia op een rij:
Verzekerd van kwaliteit door reviews
Stuvia-klanten hebben meer dan 700.000 samenvattingen beoordeeld. Zo weet je zeker dat je de beste documenten koopt!
Snel en makkelijk kopen
Je betaalt supersnel en eenmalig met iDeal, creditcard of Stuvia-tegoed voor de samenvatting. Zonder lidmaatschap.
Focus op de essentie
Samenvattingen worden geschreven voor en door anderen. Daarom zijn de samenvattingen altijd betrouwbaar en actueel. Zo kom je snel tot de kern!
Veelgestelde vragen
Wat krijg ik als ik dit document koop?
Je krijgt een PDF, die direct beschikbaar is na je aankoop. Het gekochte document is altijd, overal en oneindig toegankelijk via je profiel.
Tevredenheidsgarantie: hoe werkt dat?
Onze tevredenheidsgarantie zorgt ervoor dat je altijd een studiedocument vindt dat goed bij je past. Je vult een formulier in en onze klantenservice regelt de rest.
Van wie koop ik deze samenvatting?
Stuvia is een marktplaats, je koop dit document dus niet van ons, maar van verkoper GuusJan1. Stuvia faciliteert de betaling aan de verkoper.
Zit ik meteen vast aan een abonnement?
Nee, je koopt alleen deze samenvatting voor €2,99. Je zit daarna nergens aan vast.
Is Stuvia te vertrouwen?
4,6 sterren op Google & Trustpilot (+1000 reviews)
Afgelopen 30 dagen zijn er 52510 samenvattingen verkocht
Opgericht in 2010, al 14 jaar dé plek om samenvattingen te kopen